Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer

Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Melbinger-Zeinitzer, E, Marth, C, Samonigg, H, Kubista, E, Gnant, M